TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is open to representing investors who have lost money in Travere's stock, regardless of whether they have sold their shares [3][4]. Group 3: Investor Actions - Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery options [5]. - Whistleblowers with non-public information about Travere Therapeutics are invited to assist in the investigation, with the possibility of receiving rewards from the SEC [6]. Group 4: Firm Credentials - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].